Crossmark

Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol

Crossref DOI link: https://doi.org/10.1186/s12885-020-07772-7

Published Online: 2021-01-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cheng, Xiangdong

Wu, Dan

Xu, Nong

Chen, Luchuan

Yan, Zhilong

Chen, Ping

Zhou, Lei

Yu, Jianfa

Cui, Jiuwei

Li, Wei

Wang, Chang

Feng, Wenming

Wei, Yunhai

Yu, Pengfei

Du, Yian

Ying, Jieer

Xu, Zhiyuan

Yang, Litao

Zhang, Yunli
License Information

Text and Data Mining valid from 2021-01-12

Version of Record valid from 2021-01-12
More Information

Article History

Received: 16 June 2020

Accepted: 26 December 2020

First Online: 12 January 2021

Ethics approval and consent to participate

: Written informed consent is obtained from all patients before enrollment, patients consented with the anonymous use of their data for study purposes. The study has been approved by the Institutional Review Board at the Cancer Hospital of the University of Chinese Academy of Sciences (accepted number: 2019–139), and was undertaken in accordance with the Helsinki declaration and the Chinese Good Clinical Practice Guidelines. Ethics approval will be sought from each participating center prior to the study beginning at the site.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below